Compound C Protects Mice from HFD-Induced Obesity and Nonalcoholic Fatty Liver Disease.

Wang F, Liu Y, Yuan J, Yang W, Mo Z

International journal of endocrinology14 Aug 2019Cited by 22 (Europe PMC)

PMID31485221PMCIDPMC6710782DOI10.1155/2019/3206587PepBankPUB-31485221

Summary

ObjectivesThe aim of this study was to investigate the effects of compound C on an in vivo mouse model of high-fat diet- (HFD-) induced obesity and hepatosteatosis.MethodsC57BL/6 mice were fed with a standard diet (n = 5) for 16 weeks and then injected saline once a day for 4 weeks as the normal chow group. Mice (n = 10) were fed with HFD for 16 weeks to induce obesity and hepatosteatosis and then divided into two groups: HFD + vehicle group injected with the vehicle solution (saline) and HFD + compound C group injected with compound C in saline (5 mg/kg i.p., once a day) for 4 weeks. Liver histology was observed. The expression levels of genes related to lipid metabolism and proinflammation in liver tissue were examined. NLRP3 inflammasome expression in liver tissue was detected by the western blot assay. HepG2 cells were pretreated with compound C and/or AICAR for 1 h and then treated with palmitic acid (PA) for 3 h. The cells were collected, and mRNA levels were determined.ResultsThere was a significant reduction in body-weight gain and daily food intake in the HFD + compound C group compared with the HFD + vehicle group (p p < 0.05). Compound C enhanced mRNA levels of SOD1, SOD2, catalase, GPx1, and GPx4 and reduced the p-AMPK/AMPK ratio, which were stimulated by palmitic acid (PA). The effect was enhanced by AICAR.ConclusionOur data suggest that compound C is a potent NAFLD suppressor and an attractive therapeutic target for hepatic steatosis and related metabolic disorders.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Mechanism
In PA-treated HepG2 cells, AICAR enhanced the molecular effects of compound C without an outcome-specific breakdown.
In plain wordsIn cells treated with palmitic acid, AICAR enhanced compound C effects, but the abstract did not specify each affected outcome.
Peptide
AICAR (acadesine)
Outcome
Direction not reportedEnhancement of compound C molecular effects
Study
humann: not reported in source
Palmitic acid-treated HepG2 cells
Comparator
Compound C without AICAR
Outcome group
Receptor activity and mechanism · Liver
Studied dose
Dose not stated
Source sentences
Summary
The effect was enhanced by AICAR.
2 context sentences(design, population, supporting numbers)
Summary · context
Compound C enhanced mRNA levels of SOD1, SOD2, catalase, GPx1, and GPx4 and reduced the p-AMPK/AMPK ratio, which were stimulated by palmitic acid (PA).
Summary · context
HepG2 cells were pretreated with compound C and/or AICAR for 1 h and then treated with palmitic acid (PA) for 3 h.
Show in the study text Report a problemFND-3148522101

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.